Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Mousa, SA; Bozarth, JM; Naik, UP; Slee, A
   Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic:distinct binding profile for Roxifiban
   BRITISH JOURNAL OF PHARMACOLOGY
   
   S.A. Mousa et al., "Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic:distinct binding profile for Roxifiban", BR J PHARM, 133(3), 2001, pp. 331-336
2. Mousa, SA; Bozarth, JM; Forsythe, MS; Slee, A
   Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: Role of plasma calcium levels
   CARDIOVASCULAR RESEARCH
   
   S.A. Mousa et al., "Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: Role of plasma calcium levels", CARDIO RES, 47(4), 2000, pp. 819-826
3. Barrett, JS; Yu, J; Kapil, R; Padovani, P; Brown, F; Ebling, WF; Corjay, MH; Reilly, TM; Bozarth, JM; Mousa, SA; Pieniaszek, HJ
   Disposition and exposure of the fibrinogen receptor antagonist XV459 on alpha(IIB)beta(3), binding sites in the guinea pig
   BIOPHARMACEUTICS & DRUG DISPOSITION
   
   J.S. Barrett et al., "Disposition and exposure of the fibrinogen receptor antagonist XV459 on alpha(IIB)beta(3), binding sites in the guinea pig", BIOPHARM DR, 20(6), 1999, pp. 309-318
4. MOUSA SA; BOZARTH JM; EDWARDS S; CARROLL T; BARRETT J
   NOVEL TC-99M-LABELED PLATELET GPIIB IIIA RECEPTOR ANTAGONISTS AS POTENTIAL IMAGING AGENTS FOR VENOUS AND ARTERIAL THROMBOSIS/
   Coronary artery disease
   
   S.A. Mousa et al., "NOVEL TC-99M-LABELED PLATELET GPIIB IIIA RECEPTOR ANTAGONISTS AS POTENTIAL IMAGING AGENTS FOR VENOUS AND ARTERIAL THROMBOSIS/", Coronary artery disease, 9(2-3), 1998, pp. 131-141
5. BOZARTH JM; COHEN M; MOUSA SA
   ROLE OF ALPHA-V-BETA-3 INTEGRIN IN ENDOTHELIAL AND SMOOTH-MUSCLE CELL-MIGRATION - POTENTIAL ROLE IN CORONARY-ARTERY DISEASES
   The FASEB journal
   
   J.M. Bozarth et al., "ROLE OF ALPHA-V-BETA-3 INTEGRIN IN ENDOTHELIAL AND SMOOTH-MUSCLE CELL-MIGRATION - POTENTIAL ROLE IN CORONARY-ARTERY DISEASES", The FASEB journal, 12(4), 1998, pp. 2336-2336
6. MOUSA SA; OLSON RE; BOZARTH JM; LORELLI W; FORSYTHE MS; RACANELLI A; GIBBS S; SCHLINGMAN K; BOZARTH T; KAPIL R; WITYAK J; SIELECKI TM; WEXLER RR; THOOLEN MJ; SLEE A; REILLY TM; ANDERSON PS; FRIEDMAN PA
   ORAL ANTIPLATELET EFFICACY AND SPECIFICITY OF A NOVEL NONPEPTIDE PLATELET GPIIB IIIA RECEPTOR ANTAGONIST, DMP-802/
   Journal of cardiovascular pharmacology
   
   S.A. Mousa et al., "ORAL ANTIPLATELET EFFICACY AND SPECIFICITY OF A NOVEL NONPEPTIDE PLATELET GPIIB IIIA RECEPTOR ANTAGONIST, DMP-802/", Journal of cardiovascular pharmacology, 32(2), 1998, pp. 169-176
7. MOUSA SA; SOMASUNDARAM P; SUNG BH; BOZARTH JM; LORELLI W; WILSON MF
   ELEVATION OF CIRCULATING SMOOTH-MUSCLE CELL CHEMOATTRACTANTS MITOGENSAND ENDOTHELIAL-CELL DYSFUNCTION IN CONGESTIVE-HEART-FAILURE PATIENTS- POTENTIAL ROLE OF ALPHA-V-BETA-3 INTEGRIN/
   Naunyn-Schmiedeberg's archives of pharmacology
   
   S.A. Mousa et al., "ELEVATION OF CIRCULATING SMOOTH-MUSCLE CELL CHEMOATTRACTANTS MITOGENSAND ENDOTHELIAL-CELL DYSFUNCTION IN CONGESTIVE-HEART-FAILURE PATIENTS- POTENTIAL ROLE OF ALPHA-V-BETA-3 INTEGRIN/", Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 4919-4919
8. MOUSA SA; BOZARTH JM; BENNETT JS
   ACTIVATION-DEPENDENT ALPHA-V-BETA-3 ON PLATELETS AND LYMPHOCYTES BINDS VITRONECTIN AND OSTEOPONTIN
   Naunyn-Schmiedeberg's archives of pharmacology
   
   S.A. Mousa et al., "ACTIVATION-DEPENDENT ALPHA-V-BETA-3 ON PLATELETS AND LYMPHOCYTES BINDS VITRONECTIN AND OSTEOPONTIN", Naunyn-Schmiedeberg's archives of pharmacology, 358(1), 1998, pp. 4216-4216
9. MOUSA SA; BOZARTH JM; LORELLI W; FORSYTHE MS; THOOLEN MJMC; SLEE AM; REILLY TM; FRIEDMAN PA
   ANTIPLATELET EFFICACY OF XV459, A NOVEL NONPEPTIDE PLATELET GPIIB IIAANTAGONIST - COMPARATIVE PLATELET BINDING PROFILES WITH C7E3/
   The Journal of pharmacology and experimental therapeutics
   
   S.A. Mousa et al., "ANTIPLATELET EFFICACY OF XV459, A NOVEL NONPEPTIDE PLATELET GPIIB IIAANTAGONIST - COMPARATIVE PLATELET BINDING PROFILES WITH C7E3/", The Journal of pharmacology and experimental therapeutics, 286(3), 1998, pp. 1277-1284
10. MOUSA SA; BOZARTH JM; DEGRADO W; BENNETT JS
    ACTIVATION-DEPENDENT ALPHA-V BETA-3 ON PLATELETS AND LYMPHOCYTES BINDS VITRONECTIN AND OSTEOPONTIN
    Circulation
    
    S.A. Mousa et al., "ACTIVATION-DEPENDENT ALPHA-V BETA-3 ON PLATELETS AND LYMPHOCYTES BINDS VITRONECTIN AND OSTEOPONTIN", Circulation, 96(8), 1997, pp. 623-623
11. MOUSA SA; BOZARTH JM; FORSYTHE MS; THOOLEN M; REILLY TM; WITYAK J; OLSON RE; SIELECKI TM
    XV454, A NOVEL NONPEPTIDE ANTIPLATELET AGENT WITH COMPARABLE PLATELETALPHA-IIB-BETA-3 BINDING-KINETICS TO C7E3 AND LONG-LASTING ANTIPLATELET EFFICACY AFTER SINGLE INTRAVENOUS OR ORAL-ADMINISTRATION IN NONHUMAN-PRIMATES
    Circulation
    
    S.A. Mousa et al., "XV454, A NOVEL NONPEPTIDE ANTIPLATELET AGENT WITH COMPARABLE PLATELETALPHA-IIB-BETA-3 BINDING-KINETICS TO C7E3 AND LONG-LASTING ANTIPLATELET EFFICACY AFTER SINGLE INTRAVENOUS OR ORAL-ADMINISTRATION IN NONHUMAN-PRIMATES", Circulation, 96(8), 1997, pp. 928-928
12. REILLY TM; MOUSA SA; RACANELLI AL; THOOLEN MJ; FLINT SK; BOZARTH JM; MU DX; WALTON HL
    A MONOCLONAL-ANTIBODY THAT RECOGNIZES THE GPIIB IIIA ANTAGONIST DMP-728 - REVERSAL OF THE EFFECTS OF DMP-728 ON PLATELET-AGGREGATION AND BLEEDING-TIME IN THE DOG/
    Arteriosclerosis, thrombosis, and vascular biology
    
    T.M. Reilly et al., "A MONOCLONAL-ANTIBODY THAT RECOGNIZES THE GPIIB IIIA ANTAGONIST DMP-728 - REVERSAL OF THE EFFECTS OF DMP-728 ON PLATELET-AGGREGATION AND BLEEDING-TIME IN THE DOG/", Arteriosclerosis, thrombosis, and vascular biology, 15(12), 1995, pp. 2195-2199
13. MOUSA SA; BOZARTH JM; MU DX; LEAMY AW; ROTE WE; LUCCHESI BR; REILLY TM
    INTRAVENOUS AND ORAL ANTITHROMBOTIC EFFICACY OF THE PLATELET GPIIB IIIA ANTAGONIST, DMP728, IN DIFFERENT MODELS OF ARTERIAL THROMBOSIS/
    The FASEB journal
    
    S.A. Mousa et al., "INTRAVENOUS AND ORAL ANTITHROMBOTIC EFFICACY OF THE PLATELET GPIIB IIIA ANTAGONIST, DMP728, IN DIFFERENT MODELS OF ARTERIAL THROMBOSIS/", The FASEB journal, 9(4), 1995, pp. 837-837
14. TSAO PW; BOZARTH JM; JACKSON SA; FORSYTHE MS; FLINT SK; MOUSA SA
    PLATELET GPIIB IIIA RECEPTOR OCCUPANCY STUDIES USING A NOVEL FLUORESCEINATED CYCLIC ARG-GLY-ASP PEPTIDE/
    Thrombosis research
    
    P.W. Tsao et al., "PLATELET GPIIB IIIA RECEPTOR OCCUPANCY STUDIES USING A NOVEL FLUORESCEINATED CYCLIC ARG-GLY-ASP PEPTIDE/", Thrombosis research, 77(6), 1995, pp. 543-556
15. MOUSA SA; FORSYTHE MS; DIEMER M; BOZARTH JM; REILLY TM
    THROMBOLYTIC AND ANTITHROMBOTIC EFFICACY OF THE PLATELET GPIIB-IIIA ANTAGONIST DMP728
    Coronary artery disease
    
    S.A. Mousa et al., "THROMBOLYTIC AND ANTITHROMBOTIC EFFICACY OF THE PLATELET GPIIB-IIIA ANTAGONIST DMP728", Coronary artery disease, 5(11), 1994, pp. 919-927
16. MOUSA SA; BOZARTH JM; FORSYTHE MS; JACKSON SM; LEAMY A; DIEMER MM; KAPIL RP; KNABB RM; MAYO MC; PIERCE SK; DEGRADO WF; THOOLEN MJ; REILLY TM
    ANTIPLATELET AND ANTITHROMBOTIC EFFICACY OF DMP-728, A NOVEL PLATELETGPIIB IIIA RECEPTOR ANTAGONIST/
    Circulation
    
    S.A. Mousa et al., "ANTIPLATELET AND ANTITHROMBOTIC EFFICACY OF DMP-728, A NOVEL PLATELETGPIIB IIIA RECEPTOR ANTAGONIST/", Circulation, 89(1), 1994, pp. 3-12
17. PEASE LJ; ROBINSON CS; GILLIES PJ; BOZARTH JM; REILLY TM; MOUSA SA
    INCREASED PLATELET GPIIB IIIA RECEPTOR SENSITIVITY IN WATANABE HERITABLE HYPERLIPIDEMIC RABBITS/
    Biochemical archives
    
    L.J. Pease et al., "INCREASED PLATELET GPIIB IIIA RECEPTOR SENSITIVITY IN WATANABE HERITABLE HYPERLIPIDEMIC RABBITS/", Biochemical archives, 9(4), 1993, pp. 311-320
18. MOUSA SA; FORSYTHE MS; BOZARTH JM; REILLY TM
    EFFECT OF SINGLE ORAL DOSE OF ASPIRIN ON HUMAN PLATELET FUNCTIONS ANDPLASMA PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1)
    Thrombosis and haemostasis
    
    S.A. Mousa et al., "EFFECT OF SINGLE ORAL DOSE OF ASPIRIN ON HUMAN PLATELET FUNCTIONS ANDPLASMA PLASMINOGEN-ACTIVATOR INHIBITOR-1 (PAI-1)", Thrombosis and haemostasis, 69(6), 1993, pp. 903-903
19. MOUSA SA; BOZARTH JM; MAYO MC; FORSYTHE MS; REILLY TM
    COMPARATIVE ANTIPLATELET EFFECTS OF DIFFERENT THROMBIN INHIBITORS - KINETIC-ANALYSIS
    Thrombosis and haemostasis
    
    S.A. Mousa et al., "COMPARATIVE ANTIPLATELET EFFECTS OF DIFFERENT THROMBIN INHIBITORS - KINETIC-ANALYSIS", Thrombosis and haemostasis, 69(6), 1993, pp. 1070-1070
20. MOUSA SA; MAYO MC; BOZARTH JM; FORSYTHE MS; REILLY TM
    ANTIPLATELET EFFECTS OF THROMBIN INHIBITORS VERSUS GPIIB IIIA RECEPTOR ANTAGONISTS - COMPARATIVE KINETIC AND MECHANISTIC ANALYSIS/
    Thrombosis and haemostasis
    
    S.A. Mousa et al., "ANTIPLATELET EFFECTS OF THROMBIN INHIBITORS VERSUS GPIIB IIIA RECEPTOR ANTAGONISTS - COMPARATIVE KINETIC AND MECHANISTIC ANALYSIS/", Thrombosis and haemostasis, 69(6), 1993, pp. 1321-1321
21. MOUSA SA; DEGRADO WF; JACKSON SA; THOOLEN MJ; PIERCE SK; BOZARTH JM; HASSELL SM; REILLY TM
    ANTIPLATELET EFFICACY AND SAFETY OF THE PLATELET GPIIB IIIA ANTAGONIST, DMP-728 IN ANESTHETIZED DOGS/
    Circulation
    
    S.A. Mousa et al., "ANTIPLATELET EFFICACY AND SAFETY OF THE PLATELET GPIIB IIIA ANTAGONIST, DMP-728 IN ANESTHETIZED DOGS/", Circulation, 88(4), 1993, pp. 319-319
22. MOUSA SA; FORSYTHE MS; BOZARTH JM; REILLY TM
    EFFECT OF SINGLE ORAL DOSE OF ASPIRIN ON HUMAN PLATELET FUNCTIONS ANDPLASMA PLASMINOGEN-ACTIVATOR INHIBITOR-1
    Cardiology
    
    S.A. Mousa et al., "EFFECT OF SINGLE ORAL DOSE OF ASPIRIN ON HUMAN PLATELET FUNCTIONS ANDPLASMA PLASMINOGEN-ACTIVATOR INHIBITOR-1", Cardiology, 83(5-6), 1993, pp. 367-373
23. MOUSA SA; BOZARTH JM; FORSYTHE MS; LORELLI W; THOOLEN MJ; RAMACHANDRAN N; JACKSON S; DEGRADO W; REILLY TM
    ANTIPLATELET EFFICACY AND SPECIFICITY OF DMP728, A NOVEL PLATELET GPIIB IIIA RECEPTOR ANTAGONIST/
    Cardiology
    
    S.A. Mousa et al., "ANTIPLATELET EFFICACY AND SPECIFICITY OF DMP728, A NOVEL PLATELET GPIIB IIIA RECEPTOR ANTAGONIST/", Cardiology, 83(5-6), 1993, pp. 374-382